Clinical trials
Metastatic Gastric Adenocarcinoma clinical trials
Below are recruiting metastatic gastric adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 157 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06901531RecruitingPhase 3
Study of zolbetuximab with pembrolizumab and chemo for gastric cancer
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
Birmingham, AlabamaAges 18 years+ - NCT04047953Recruiting
Chemo for stomach cancer to make tumors easier to remove
This trial tests a combination chemotherapy plan—paclitaxel (albumin-bound), oxaliplatin, and S-1 given before surgery—to try to shrink stomach cancer and improve the chance of successful tumor removal. It is for people whose cancer is locally advanced or has spread, but might still be resectable (removable) in certain cases.
Beijing, Beijing MunicipalityAges 18–75 - NCT04840264RecruitingPhase 2
Chemotherapy for stomach cancer with blocked intestines
This Phase 2 trial tests a chemotherapy combination (docetaxel, oxaliplatin, and 5-FU) in people with stomach or gastroesophageal cancer that has spread to the lining of the abdomen and is causing an inoperable bowel blockage. It aims to shrink or control the blockage and cancer when surgery cannot be done.
Guangzhou, GuangdongAges 18–75 - NCT05482516RecruitingPhase 3
Testing blood test–guided treatment for GI cancers in remission
This Phase 3 study tests whether giving treatment based on a positive blood test for “minimal cancer signals” (ctDNA) can help people with certain GI cancers stay cancer-free longer. It focuses on people who have finished curative-intent therapy and currently have no visible disease on scans, but their blood test is still positive.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06038578RecruitingPhase 2
TRK-950 with standard chemo for advanced stomach cancer
This trial tests a new drug, TRK-950, added to standard chemotherapy (ramucirumab and paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has worsened after previous treatment. The goal is to see if this combination can help shrink tumors or slow disease progression.
Duarte, CaliforniaAges 18 years+ - NCT06121700RecruitingPhase 2
Chemoimmunotherapy and radiation before surgery for limited spread stomach cancer
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
ShanghaiAges 18–75 - NCT06177041RecruitingPhase 3
M108 plus chemo for CLDN18.2-positive stomach cancer
This trial tests a new drug (M108) combined with standard chemotherapy (CAPOX) as a first treatment for people with advanced stomach or gastroesophageal junction cancer that has a specific protein called Claudin 18.2. The goal is to see if adding M108 helps improve outcomes compared to chemotherapy alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT06266299RecruitingPhase 1
Study of KK2269 for adults with solid tumors
This trial tests a new drug called KK2269 for adults with solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective, possibly as a treatment option for certain cancers like lung or stomach cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06364410RecruitingPhase 1
Testing a new drug combo for stomach and other solid tumors
This trial tests a combination of two drugs, trastuzumab deruxtecan and azenosertib, for people with stomach cancer or other solid tumors that have a specific protein called HER2. It aims to see if this combination can help when other treatments have stopped working.
Houston, TexasAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Little Rock, ArkansasAges 18 years+ - NCT07529808RecruitingPhase 1/Phase 2
New Drug BHB810 for Advanced Stomach Cancer
This trial tests a new drug called BHB810 for gastric (stomach) and gastroesophageal junction cancer that has stopped responding to standard treatments or has no standard options available. The drug targets a protein called CDH17 found on cancer cells and may help slow or shrink the tumor.
Fairfax, VirginiaAges 18 years+ - NCT06702683Recruiting
Sintilimab blood levels in advanced stomach cancer
This study looks at how the amount of Sintilimab in your blood relates to how well it works and what side effects you might have. If you have advanced stomach cancer and are planning to get Sintilimab, this trial could help your doctor find the best dose for you.
Nanjing, JiangsuAges 18 years+ - NCT06773312RecruitingPhase 1
Study of BC001 plus Sintilimab and XELOX for advanced stomach cancer
This trial tests a combination of three drugs (BC001, Sintilimab, and XELOX chemotherapy) for people with advanced or metastatic HER-2 negative stomach cancer or cancer where the stomach meets the esophagus. The goal is to see if this combination works better than standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06846346RecruitingPhase 2
Testing Ivonescimab with Chemo for Advanced Stomach Cancer
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
LyonAges 18 years+ - NCT06921837RecruitingPhase 1/Phase 2
BDC-4182 for advanced gastric or gastroesophageal cancer
This trial tests a new drug called BDC-4182 for advanced gastric or gastroesophageal cancer. It is for people who have already tried standard treatments and may target a protein called Claudin 18 on some cancer cells.
Darlinghurst, New South WalesAges 18 years+ - NCT07000253RecruitingPhase 2/Phase 3
Timing of local treatment for limited metastatic stomach or esophageal cancer
This trial tests whether giving local treatments (like surgery or radiation) to cancer spots later—after starting immunotherapy or targeted therapy—helps people with stomach or esophageal cancer that has spread to a few places. It aims to improve outcomes by timing treatments carefully.
AmsterdamAges 18 years+ - NCT07102901RecruitingPhase 2
Study of SHR2554 with other therapies for gastric or junction cancer
This trial tests a new drug, SHR2554, combined with other anticancer treatments for advanced stomach or gastroesophageal junction cancer. It aims to see if the combination is safe and effective. You may qualify if you have measurable disease and are generally in good health.
Harbin, HeilongjiangAges 18–75 - NCT07149090RecruitingPhase 1/Phase 2
Lenvatinib, Nivolumab, and Chemo in Stomach Cancer with Ascites
This trial tests a combination of two drugs (lenvatinib and nivolumab) plus chemotherapy for people with advanced stomach cancer that has caused fluid buildup in the belly. The goal is to see if this combination can help shrink the cancer and reduce the fluid.
SeoulAges 19 years+ - NCT07221149RecruitingPhase 2/Phase 3
Pumitamig vs Nivolumab for untreated stomach or esophagus cancer
This trial compares two treatments for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. One group gets pumitamig plus chemotherapy, the other gets nivolumab plus chemotherapy. The goal is to see which combination works better.
Phoenix, ArizonaAges 18 years+ - NCT07270991RecruitingPhase 3
Testing a new drug combo for advanced stomach or esophageal cancer
This study tests whether adding a targeted drug, fruquintinib, to the chemotherapy trifluridine/tipiracil works better than the chemotherapy alone for stomach or esophageal cancer that has spread. It's for people who have already tried a few treatments.
AurillacAges 18 years+ - NCT07282912RecruitingPhase 2
Extra treatment for certain digestive cancers with undetectable ctDNA
This trial tests if adding extra local treatments (like surgery or radiation) to usual care can improve outcomes for people with certain advanced digestive cancers that have spread to a limited number of sites. You may be eligible if your cancer has responded well to at least 4 months of therapy and your ctDNA (a sign of cancer in the blood) is undetectable.
New Haven, ConnecticutAges 18–80 - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Scottsdale, ArizonaAges 18 years+ - NCT07334431RecruitingPhase 1/Phase 2
A trial of fruquintinib, trastuzumab, and chemo for HER2-positive stomach cancer
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
Zhengzhou, HenanAges 18–75
Hear when a new Metastatic Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic gastric adenocarcinoma?
- Yes. Clin2 currently lists 157 recruiting metastatic gastric adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic gastric adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic gastric adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.